Vol 14, No 1 (2017)
Review paper
Published online: 2017-03-01
Page views
1339
Article views/downloads
7196
Partial agonism and full efficacy. Pharmacological profile and clinical application of aripiprazole
Psychiatria 2017;14(1):1-6.
Abstract
Aripiprazole has among other antipsychotic agents a unique receptor profile, which results in its therapeutic effect and tolerability. In a situation of excess dopamine the compound acts similarly to other antipsychotics, whereas in dopamine deficit it exhibits agonistic properties. Numerous studies have documented that aripiprazole is efficacious for schizophrenia and bipolar disorder treatment. In a dose dependent manner, it may be used in the acute phase of illness or in maintenance therapy. The partial D2 receptor agonism prevents the occurrence of dopaminergic deficit resulting in less common parkinsonism, hyperprolactinemia and up-regulation of dopamine receptors. Aripiprazole has no clinically significant influence on weight gain, cardio-vascular disorders or metabolic parameters. This article presents the therapeutic applications of aripiprazole with emphasis on its administration during acute psychosis and mania, its dose-dependent effect and profile of tolerability.
Keywords: aripiprazoleschizophreniabipolar disorder
References
- Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry. 2002; 63(12): 1121–1128.
- Arypiprazol – charakterystyka produktu leczniczego FDA; https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021436s038,021713s030,021729s022,021866s023lbl.pdf; 25.11.2016.
- Akyol Ardic U, Ercan ES, Kutlu A, et al. Successful Treatment Response with Aripiprazole Augmentation of SSRIs in Refractory Obsessive-Compulsive Disorder in Childhood. Child Psychiatry Hum Dev. 2016 [Epub ahead of print].
- Prommer E. Aripiprazole: A New Option in Delirium. Am J Hosp Palliat Care. 2015 [Epub ahead of print].
- de Bartolomeis A, Tomasetti C, Iasevoli F. Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015; 29(9): 773–799.
- Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. 1999; 20(6): 612–627.
- Crow TJ. An evaluation of the dopamine hypothesis of schizophrenia. The Biological Basis of Schizophrenia. 1978: 63–78.
- Chrzanowski WK, Marcus RN, Torbeyns A, et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl.). 2006; 189(2): 259–266.
- Di Sciascio G, Riva MA. Aripiprazole: from pharmacological profile to clinical use. Neuropsychiatr Dis Treat. 2015; 11: 2635–2647.
- Mizrahi R, Mamo D, Rusjan P, et al. The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics. Int J Neuropsychopharmacol. 2009; 12(5): 715–721.
- Newman-Tancredi A. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. Curr Opin Investig Drugs. 2010; 11(7): 802–812.
- Stip E, Tourjman V. Aripiprazole in schizophrenia and schizoaffective disorder: A review. Clin Ther. 2010; 32 Suppl 1: S3–20.
- Yatham L, Kennedy S, Parikh S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disorders. 2012; 15(1): 1–44.
- Park SW, Phuong VuT, Lee CH, et al. Effects of antipsychotic drugs on BDNF, GSK-3β, and β-catenin expression in rats subjected to immobilization stress. Neurosci Res. 2011; 71(4): 335–340.
- Jarema M. Standardy leczenia farmakologicznego niektórych zaburzeń psychicznych. Wyd. 2, Via Medica, Gdańsk 2015.
- Poyurovsky M, Bergman J, Pashinian A, et al. Beneficial effect of low-dose mirtazapine in acute aripiprazole-induced akathisia. Int Clin Psychopharmacol. 2014; 29(5): 296–298.
- Citrome L, Eramo A, Francois C, et al. Lack of tolerable treatment options for patients with schizophrenia. Neuropsychiatr Dis Treat. 2015; 11: 3095–3104.
- Englisch S, Zink M. Combined antipsychotic treatment involving clozapine and aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32(6): 1386–1392.
- Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013; 382(9896): 951–962.
- Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol. 2003; 6(4): 325–337.
- Sparshatt A, Taylor D, Patel MX, et al. A systematic review of aripiprazole--dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry. 2010; 71(11): 1447–1456.
- Kerwin R, Millet B, Herman E, et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. Eur Psychiatry. 2007; 22(7): 433–443.
- Newcomer JW, Campos JA, Marcus RN, et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry. 2008; 69(7): 1046–1056.
